Thursday, July 17, 2025 10:15:59 AM
FeMike, the reason this means something different now than it might have a year ago is because of timing, sequence, and the structure of the MHRA review process. This is not about reinterpreting the same words arbitrarily. It is about what those words mean at this specific point in the review.
Let’s look again at the exact phrasing NICE used on July 15, 2025:
“NWBO reports that it is still fully occupied and engaged in the Marketing Authorisation Application (MAA) process with the MHRA”
“The company are not yet in a position to provide their evidence submission with us”
“We await further contact from them”
You asked why this same language could not describe the company’s state a year ago. It could have, but it would have reflected an earlier part of the process. That is how structured regulatory systems work. The MAA process is sequential. What comes before submission is not the same as what comes after review.
MHRA marketing authorisation follows a defined order
1. Pre-submission
2. Validation
3. Review and clock phases
4. End of procedure
5. Label finalisation (SmPC)
6. Marketing authorisation granted
7. NICE engagement
The July 15 letter confirms that NWBO is still within the MAA process and has not submitted their evidence to NICE. But NICE also says they await further contact. That means they are waiting for NWBO to finish work with MHRA before NICE can proceed. At this point in the timeline, the only work that remains is the finalisation of the Summary of Product Characteristics, or SmPC. That is labeling.
Why? Because NICE cannot appraise a product until the company submits either a draft or final SmPC along with its evidence package. This is a published requirement in NICE’s STA process guide.
Quote
“The company should submit evidence including the final or draft Summary of Product Characteristics”
Source
https://www.nice.org.uk/process/pmg24/resources/single-technology-appraisal-and-highly-specialised-technologies-evaluation-user-guide-for-company-evidence-submission-pdf-72286713172933
So to your question
Were they also fully occupied and engaged a year ago? Yes
But the meaning has changed, because the process has advanced
A year ago that phrase described pre-review coordination
Today it describes post-review implementation
And NICE’s own statement confirms it
This is not speculation
It is procedural logic
And at this point the only remaining phase is labeling
Let’s look again at the exact phrasing NICE used on July 15, 2025:
“NWBO reports that it is still fully occupied and engaged in the Marketing Authorisation Application (MAA) process with the MHRA”
“The company are not yet in a position to provide their evidence submission with us”
“We await further contact from them”
You asked why this same language could not describe the company’s state a year ago. It could have, but it would have reflected an earlier part of the process. That is how structured regulatory systems work. The MAA process is sequential. What comes before submission is not the same as what comes after review.
MHRA marketing authorisation follows a defined order
1. Pre-submission
2. Validation
3. Review and clock phases
4. End of procedure
5. Label finalisation (SmPC)
6. Marketing authorisation granted
7. NICE engagement
The July 15 letter confirms that NWBO is still within the MAA process and has not submitted their evidence to NICE. But NICE also says they await further contact. That means they are waiting for NWBO to finish work with MHRA before NICE can proceed. At this point in the timeline, the only work that remains is the finalisation of the Summary of Product Characteristics, or SmPC. That is labeling.
Why? Because NICE cannot appraise a product until the company submits either a draft or final SmPC along with its evidence package. This is a published requirement in NICE’s STA process guide.
Quote
“The company should submit evidence including the final or draft Summary of Product Characteristics”
Source
https://www.nice.org.uk/process/pmg24/resources/single-technology-appraisal-and-highly-specialised-technologies-evaluation-user-guide-for-company-evidence-submission-pdf-72286713172933
So to your question
Were they also fully occupied and engaged a year ago? Yes
But the meaning has changed, because the process has advanced
A year ago that phrase described pre-review coordination
Today it describes post-review implementation
And NICE’s own statement confirms it
This is not speculation
It is procedural logic
And at this point the only remaining phase is labeling
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
